Antibody-mediated rejection (AMR)—or humoral rejection—after renal transplantation is a devastating event that inevitably led to allograft loss. AMR poses a significant and continued challenge for long term graft survival in kidney transplantation. Allograft rejection is a complex process that involves the interplay of different cellular and molecular pathways that cause a broad range of allograft injuries (acute tubular injury, glomerulitis, capillaritis, and fibrinoid necrosis).
Treatment of AMR is often initiated in situations of diffuse C4d positivity with allograft dysfunction even in the absence of DSA or histological evidence of AMR. The inability to measure DSAs in these cases may be related to the presence of non-anti-HLA antibodies, to antigen not present on the single-bead assays, or to the possibility that the DSAs may be completely absorbed onto the allograft.
Get FREE sample copy at:
The Antibody-Mediated Rejection market report also covers emerging drugs, current treatment practices, Antibody-Mediated Rejection market share of the individual therapies, current and forecasted Antibody-Mediated Rejection Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Antibody-Mediated Rejection treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Antibody-Mediated Rejection Market Key Facts
As per the study conducted by Valenzuela et al. (2017), the incidence tends to be higher (up to 40%) in pediatric and medication-non-adherence adult transplant patients, with the latter constituting nearly two-thirds of adult transplant patients by 12 years after transplantation. AMR incidence among pre-sensitized patients is more than 20%.
According to the study conducted by Puttarajappa et al. (2012), acute AMR occurs in about 5–7% of all kidney transplants and is responsible for 20–48% of acute rejection episodes among pre-sensitized positive crossmatch patients.
As per the study conducted by Calp-Inal et al. (2016), the incidence of acute and chronic AMR was 45% and 36% in patients with C1q+DSA. The study indicated that the presence of C1q+ DSA was associated with acute and chronic AMR.
Key Benefits of Antibody-Mediated Rejection Market Report
Antibody-Mediated Rejection market report provides an in-depth analysis of Antibody-Mediated Rejection Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Antibody-Mediated Rejection market report will help in developing business strategies by understanding the Antibody-Mediated Rejection Market trends & developments, key players and future market competition that will shape and drive the Antibody-Mediated Rejection market in the upcoming years.
The Antibody-Mediated Rejection market report covers Antibody-Mediated Rejection current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Antibody-Mediated Rejection market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Antibody-Mediated Rejection market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Antibody-Mediated Rejection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Antibody-Mediated Rejection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Antibody-Mediated Rejection epidemiology section covers insights about historical and current Antibody-Mediated Rejection patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Antibody-Mediated Rejection Drugs Uptake and Key Market Players
The Antibody-Mediated Rejection Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-Mediated Rejection market or expected to get launched in the market during the study period. The analysis covers Antibody-Mediated Rejection market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The primary aim of therapeutic approaches to Antibody-mediated rejection is to remove circulating donor-specific anti-HLA antibodies and to block their effects, reduce their production, or both.
Some of the key companies in the Antibody-Mediated Rejection market include:
Hansa Biopharma AB
Antibody-Mediated Rejection Therapies Covered:
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Antibody-Mediated Rejection Competitive Intelligence Analysis
4. Antibody-Mediated Rejection Market Overview at a Glance
5. Antibody-Mediated Rejection Disease Background and Overview
6. Antibody-Mediated Rejection Patient Journey
7. Antibody-Mediated Rejection Epidemiology and Patient Population
8. Antibody-Mediated Rejection Treatment Algorithm, Current Treatment, and Medical Practices
9. Antibody-Mediated Rejection Unmet Needs
10. Key Endpoints of Antibody-Mediated Rejection Treatment
11. Antibody-Mediated Rejection Marketed Products
12. Antibody-Mediated Rejection Emerging Therapies
13. Antibody-Mediated Rejection Seven Major Market Analysis
14. Attribute Analysis
15. Antibody-Mediated Rejection Market Outlook (7 major markets)
16. Antibody-Mediated Rejection Access and Reimbursement Overview
17. KOL Views on the Antibody-Mediated Rejection Market.
18. Antibody-Mediated Rejection Market Drivers
19. Antibody-Mediated Rejection Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd 2432
City: Las Vegas
Country: United States